Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2008-04-24
2010-11-16
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C435S320100
Reexamination Certificate
active
07833533
ABSTRACT:
Previously, we showed that type I interferon (alpha/beta interferon [IFN-α/β]) can inhibit foot-and-mouth disease virus (FMDV) replication in cell culture, and swine inoculated with 109PFU of human adenovirus type 5 expressing porcine IFN-α (Ad5-pIFN-α) were protected when challenged 1 day later. In this study, we found that type II pIFN (pIFN-γ) also has antiviral activity against FMDV in cell culture and that, in combination with pIFN-α, it has a synergistic antiviral effect. We also observed that while each IFN alone induced a number of IFN-stimulated genes (ISGs), the combination resulted in a synergistic induction of some ISGs. To extend these studies to susceptible animals, we inoculated groups of swine with a control Ad5, 108PFU of Ad5-pIFN-α, low- or high-dose Ad5-pIFN-γ, or a combination of Ad5-pIFN-α and low- or high-dose Ad5-pIFN-γ and challenged all groups with FMDV 1 day later. The control group and the groups inoculated with either Ad5-pIFN-α or a low dose of Ad5-pIFN-γ developed clinical disease and viremia. However, the group that received the combination of both Ad5-IFNs with the low dose of Ad5-pIFN-γ was completely protected from challenge and had no viremia. Similarly the groups inoculated with the combination of Ad5s with the higher dose of Ad5-pIFN-γ or with only high-dose Ad5-pIFN-γ were protected. The protected animals did not develop antibodies against viral nonstructural (NS) proteins, while all infected animals were NS protein seropositive. No antiviral activity or significant levels of IFNs were detected in the protected groups, but there was an induction of some ISGs. The results indicate that the combination of type I and II IFNs act synergistically to inhibit FMDV replication in vitro and in vivo.
REFERENCES:
Yao et al, Veterinary immunology and Immunopathology, Available on-line as of Oct. 2, 2007, vol. 122, pp. 309-311.
Chinsangaram et al, Journal of Virology, 2003, vol. 77, No. 2, pp. 1621-1625.
Moraes et al, Journal of Virology, Jul. 2007, vol. 81, No. 13, pp. 7124-7135.
Grubman Marvin J.
Koster Marla J.
Moraes Mauro
Fado John D.
Rabin Evelyn M.
Salimi Ali R.
The United States of America as represented by the Secretary of
LandOfFree
Enhanced antiviral activity against foot and mouth disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhanced antiviral activity against foot and mouth disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhanced antiviral activity against foot and mouth disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4154896